1.
Lancet Infect Dis
; 24(1): e4-e5, 2024 Jan.
Article
in English
| MEDLINE
| ID: mdl-38070528
Subject(s)
COVID-19 , SARS-CoV-2 , Humans , COVID-19/prevention & control , Vaccination , Antibodies, Viral , Antibodies, Neutralizing , Immunity, Mucosal
2.
Cancer Cell
; 41(5): 821-823, 2023 05 08.
Article
in English
| MEDLINE
| ID: mdl-37116490
ABSTRACT
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.